Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

November 19, 2013

WALTHAM, Mass., Nov 19, 2013 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]

Tetraphase Reports Third-Quarter 2013 Financial Results

Tetraphase Reports Third-Quarter 2013 Financial Results

November 14, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended September 30, 2013.

BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer

BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer

November 14, 2013

WALTHAM, Mass., Nov. 14, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that its Board of Directors has appointed Stephen P. Hall, as the company's Executive Vice President, Chief Financial Officer.

Avedro and the University of Rostock (Germany) Announce Exclusive Intellectual Property Agreement

Avedro and the University of Rostock (Germany) Announce Exclusive Intellectual Property Agreement

November 14, 2013

Avedro will Commercialize Patented Corneal Biomechanical Diagnostic

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that it has obtained an exclusive license to commercialize scientific patents created at the University of Rostock (Germany). The devices, which will in part be based on these patents, will allow Avedro to bring to market the first ever diagnostic device to accurately assess corneal biomechanical strength.

Avedro Announces the Start of Two New US FDA Trials for Accelerated Cross-linking

Avedro Announces the Start of Two New US FDA Trials for Accelerated Cross-linking

November 12, 2013

Lasik with Cross-linking and Pulsed Accelerated Cross-linking

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.

TransMedics, Inc. Appointed Jeffrey E. Young as Chief Financial Officer

TransMedics, Inc. Appointed Jeffrey E. Young as Chief Financial Officer

November 8, 2013

ANDOVER, Mass., Nov. 8, 2013 /PRNewswire/ -- TransMedics, Inc., an emerging medical technology company dedicated to extending the life-saving benefits of organ transplantation to patients suffering from end-stage organ failure, announced today that Jeffrey E. Young was appointed to the position of Chief Financial Officer and Treasurer, effective August 2013. Mr. Young, is responsible for the Company's finance, accounting, and treasury functions and reports directly to Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics, Inc.

Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results

Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results

November 7, 2013

Successfully Completed Initial Public Offering and Advanced IDH2 Cancer Metabolism Program into Clinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2013.

Black Duck Maintains Rapid Pace With Record-Breaking Third Quarter

Black Duck Maintains Rapid Pace With Record-Breaking Third Quarter

November 7, 2013

New Customer Acquisition, Growth in EMEA and Asia-Pacific, and Expansion in Financial Services, Retail, Online Services, Automotive and Health Care Propel Growth

Tetraphase Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Tetraphase Pharmaceuticals Announces Pricing of Public Offering of Common Stock

November 7, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, less underwriting discounts and commissions. The size of the offering was upsized from 3.3 million shares to 4.5 million shares, raising aggregate gross proceeds of $45 million. Tetraphase has granted the underwriters a 30-day option to purchase 675,000 additional shares of common stock on the same terms and conditions.

BG Medicine Reports 2013 Third Quarter Financial Results

BG Medicine Reports 2013 Third Quarter Financial Results

November 6, 2013

Capital Health Accountable Care Organization LLC Adopts BGM Galectin-3® Test

Network of Laboratories in U.S. Offering BGM Galectin-3Test Expanded

Full-Year 2013 Product Revenue and Cash Burn Guidance Confirmed

WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today reported financial results for the third quarter of 2013.